Ipsen Pays $855 Million for Exelixis’ Cancer Drug

07.03.2016 - French pharmaceutical company Ipsen is paying up to $855 million for the rights to Exelixis’ cancer drug Cabozantinib. Under the deal, Exelixis gains exclusive commercialization...